TY - JOUR
T1 - Use of comprehensive geriatric assessment in older cancer patients
T2 - Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)
AU - Extermann, Martine
AU - Aapro, Matti
AU - Bernabei, Roberto
AU - Cohen, Harvey Jay
AU - Droz, Jean Pierre
AU - Lichtman, Stuart
AU - Mor, Vincent
AU - Monfardini, Silvio
AU - Repetto, Lazzaro
AU - Sørbye, Liv
AU - Topinkova, Eva
PY - 2005/9
Y1 - 2005/9
N2 - Background: As more and more cancers occur in elderly people, oncologists are increasingly confronted with the necessity of integrating geriatric parameters in the treatment of their patients. Methods: The International Society of Geriatric Oncology (SIOG) created a task force to review the evidence on the use of a comprehensive geriatric assessment (CGA) in cancer patients. A systematic review of the evidence was conducted. Results: Several biological and clinical correlates of aging have been identified. Their relative weight and clinical usefulness is still poorly defined. There is strong evidence that a CGA detects many problems missed by a regular assessment in general geriatric and in cancer patients. There is also strong evidence that a CGA improves function and reduces hospitalization in the elderly. There is heterogeneous evidence that it improves survival and that it is cost-effective. There is corroborative evidence from a few studies conducted in cancer patients. Screening tools exist and were successfully used in settings such as the emergency room, but globally were poorly tested. The article contains recommendations for the use of CGA in research and clinical care for older cancer patients. Conclusions: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival. The task force cannot recommend any specific tool or approach above others at this point and general geriatric experience should be used.
AB - Background: As more and more cancers occur in elderly people, oncologists are increasingly confronted with the necessity of integrating geriatric parameters in the treatment of their patients. Methods: The International Society of Geriatric Oncology (SIOG) created a task force to review the evidence on the use of a comprehensive geriatric assessment (CGA) in cancer patients. A systematic review of the evidence was conducted. Results: Several biological and clinical correlates of aging have been identified. Their relative weight and clinical usefulness is still poorly defined. There is strong evidence that a CGA detects many problems missed by a regular assessment in general geriatric and in cancer patients. There is also strong evidence that a CGA improves function and reduces hospitalization in the elderly. There is heterogeneous evidence that it improves survival and that it is cost-effective. There is corroborative evidence from a few studies conducted in cancer patients. Screening tools exist and were successfully used in settings such as the emergency room, but globally were poorly tested. The article contains recommendations for the use of CGA in research and clinical care for older cancer patients. Conclusions: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival. The task force cannot recommend any specific tool or approach above others at this point and general geriatric experience should be used.
KW - Aged >70
KW - Cancer
KW - Comprehensive geriatric assessment
KW - Consensus
KW - Screening
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=24044454968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24044454968&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2005.06.003
DO - 10.1016/j.critrevonc.2005.06.003
M3 - Article
C2 - 16084735
AN - SCOPUS:24044454968
SN - 1040-8428
VL - 55
SP - 241
EP - 252
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 3
ER -